On Thursday, Mizuho Securities showed confidence in Intra-Cellular Therapies (NASDAQ:ITCI) by increasing its price target for the company's stock to $100 from the previous $96. The firm maintains a Buy rating on the shares. This adjustment comes following the release of encouraging Phase 3 data for the company's leading drug, lumateperone, also known as Caplyta, in treating major depressive disorder (MDD).
The analyst at Mizuho Securities has cited the second set of positive Phase 3 data released earlier this week as the reason for the heightened probability of success assumption for Caplyta in MDD, now at 90% up from the prior 80%.
This optimism has led to an upward revision of the peak annual sales estimates for Caplyta in MDD, now projected at $1.9 billion risk-unadjusted and $1.7 billion risk-adjusted, which is an increase from the former $1.5 billion risk-adjusted forecast.
The recent data has bolstered the firm's conviction in Caplyta's market potential within MDD treatment. With a 32% upside to the new 12-month price target and growing interest from strategic investors likely following the MDD data, Mizuho Securities has reiterated its Buy rating. Intra-Cellular Therapies is also listed as a top pick at the firm.
The endorsement from Mizuho Securities reflects a significant vote of confidence in Intra-Cellular Therapies' prospects, especially concerning its flagship product, Caplyta. The raised price target is indicative of the firm's belief in the drug's commercial potential and the company's future financial performance.
In other recent news, Intra-Cellular Therapies reported promising results in their Study 502, highlighting lumateperone's potential as an effective treatment for Major Depressive Disorder (MDD).
The study demonstrated significant reduction in depression severity, a result that has prompted the company to plan a supplemental New Drug Application (sNDA) submission to the U.S. Food and Drug Administration (FDA) in the second half of 2024.
In addition, Intra-Cellular Therapies reported a significant increase in Q1 revenues for 2024, reaching $144.8 million, primarily driven by the robust sales of Caplyta, its product used in the treatment of schizophrenia and bipolar disorder.
RBC Capital has maintained an Outperform rating on the company, backed by a positive evaluation of the company's Caplyta patent estate. The firm's analysis suggests a potential $3 billion total out-year opportunity for Intra-Cellular Therapies if the MDD label expansion is realized.
In other company news, Intra-Cellular Therapies has been proactive in expanding its sales force to support Caplyta, should it be approved for MDD. There are also other pipeline opportunities, such as ITI-1284 for various disorders and lenrispodun for Parkinson’s disease, coming up in the future. These recent developments indicate a strong position for the company in the market.
InvestingPro Insights
Following Mizuho Securities' optimistic outlook on Intra-Cellular Therapies (NASDAQ:ITCI), a deeper dive into the company's financials and market performance using InvestingPro data reveals a complex picture.
With a market capitalization of $8.02 billion and a Price / Book ratio of 13.37 as of the last twelve months leading into Q1 2024, Intra-Cellular stands out in its market segment. Despite a negative P/E ratio, which suggests that the company is not currently profitable, the substantial revenue growth of 65.45% over the last twelve months indicates significant market traction and potential for future profitability.
InvestingPro Tips highlight that Intra-Cellular's stock has experienced a strong return over the last month, with a 15.55% increase, and has continued to perform well over the last week with a 10.33% return. This aligns with the positive sentiment from Mizuho Securities.
Still, analysts caution that the company may not achieve profitability this year, and the stock is currently in overbought territory according to the RSI. These nuances are critical for investors to consider when evaluating the company's long-term prospects.
For those looking to delve further into Intra-Cellular Therapies' potential, there are additional InvestingPro Tips available, providing a more comprehensive analysis of the company's financial health and market performance. Interested investors can explore these tips and take advantage of a special offer using the coupon code PRONEWS24 to receive an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.